Key result
Molecular insights highlight hepatocyte VLDL assembly and secretion pathways as critical for cardiometabolic health.
Why the study?
Cardiometabolic patients frequently face both ASCVD risk from VLDL remnant particles and hepatic steatosis, highlighting the importance of understanding the molecular regulation of VLDL biogenesis.
Answers are grounded in this paper and cite their sources.
Understanding the molecular regulation of VLDL biogenesis is crucial for addressing both ASCVD risk and hepatic steatosis in cardiometabolic patients.
The production and secretion of very-low density lipoproteins (VLDL) by hepatocytes has a direct impact on liver fat content as well as the concentration of cholesterol and triglycerides in the circulation and thus affects liver and cardiovascular health, respectively. Importantly, excess caloric intake and lack of physical activity are associated with overproduction of VLDL, hepatic steatosis, and increased levels of atherogenic lipoproteins. Cholesterol as well as triglycerides in remnant particles after VLDL lipolysis are risk factors for atherosclerotic cardiovascular disease (ASCVD) and have garnered increasing attention over the last few decades. To date, however, increased risk of ASCVD is not the only concern when considering today’s cardiometabolic patients, as they often also suffer from hepatic steatosis. This notion highlights the importance of understanding the molecular regulation of VLDL biogenesis. Fortunately, there has been a resurgence of interest in the intracellular assembly, trafficking, degradation, and secretion of VLDL by hepatocytes, that has led to many exciting new molecular insights, the topic of this review. We think that increasing our understanding of the biology of this pathway will help improve the health of the cardiometabolic patient in the long term.
No takes yet. Share an insight, caveat, or question.
Zwol et al. (2023) conducted a review in Cardiometabolic disease, hepatic steatosis, and ASCVD. Recent molecular insights into the intracellular assembly, trafficking, degradation, and secretion of VLDL by hepatocytes highlight the importance of this pathway for cardiometabolic health.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: